Technology that offers tools that conform, de-identify, link and aggregate data and data science tools like AI, machine learning and advanced analytics, can help those researching rare diseases overcome the hurdles they face in discovery and development. The post Data Technology + RWD Are Positive for Rare Disease Treatment appeared first on MedCity News.
As AI chatbots become a surrogate for human connection amid a national mental health crisis, experts are worried about these tools’ lack of safeguards — with research showing the models can provide dangerous, sometimes fatal, advice. Regulators and providers alike are scrambling to catch up with a technology that evolves faster than humans are able…
Beyond the branded products currently sold by Mallinckrodt and Endo, the companies say the combined business will also have a strong foundation in rare and orphan diseases. Generic medicines will be spun out as a separate company. The post Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal appeared first…
President-Elect Donald Trump nominated celebrity physician Dr. Mehmet Oz to lead CMS. Healthcare leaders have mixed feelings on the news — for instance, one CEO pointed out that Dr. Oz could advance the food-as-medicine movement, and others noted that his appointment may decrease pharmaceutical innovation and access to certain medications. The post 5 Healthcare CEOs…
Mount Sinai researchers found that popular AI chatbots like ChatGPT and DeepSeek R1 can generate convincing but false medical information when given even a single fabricated term in a prompt. While the study underscored the need for stronger safeguards, its lead author noted that generative AI still holds major promise for reducing clinician workload if…
How does a hospital’s participation in a health plan’s Medicare Advantage (MA) provider network impact their commercial rates? Since many insurers offer both MA plans and commercial plans, there could be spillovers with respect to negotiating. How would MA network participation impact commercial rates? Marr et al. (2025) offers some hypotheses: On the one hand,…
Government documents viewed by KFF Health News show a drop in patients receiving care this year at the National Institutes of Health’s renowned research hospital, a 200-bed facility at NIH headquarters in Maryland. We previously reported a decrease in the number of patients being treated at the NIH Clinical Center from February through April. Since then,…
Financial and policy trends are shifting the M&A landscape now, says a Kaufman Hall expert
Avalayn Pharma found strong investor interest in its inhalable drugs in development for two types of pulmonary fibrosis, enabling the company to upsize its IPO. Data from two mid-stage studies are expected in 2027. The post Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials appeared first on MedCity…
By STEVEN ZECOLA Steven Zercola is back with his latest insights into research in Parkinson’s disease. You can say previous part of this series here In its latest report, the National Institute of Health (NIH) references 508 active Parkinson’s disease (PD) projects as the recipients of $243M in grants. A few caveats are warranted about…